1. Catalogs
  2. pulmonX
  3. StratX™ Lung Analysis Platform

StratX™ Lung Analysis Platform

StratX™ Lung Analysis Platform

StratX™ Lung Analysis Platform

Product catalog summary
Overview: The StratX™ Lung Analysis Platform is a cloud-based quantitative CT analysis service designed to support the selection and treatment targeting of patients for endobronchial valve (EBV) therapy. It provides clinically-validated information on emphysema destruction, fissure completeness, and lobar volumes.
Key Features:
  • Accuracy: The platform achieves 90% accuracy in identifying EBV responders and non-responders when combined with the Chartis Pulmonary Assessment System.
  • User-Friendly Design: The platform is designed for ease of use and clear interpretation across different CT scanners and hospitals.
  • Clinically-Validated Algorithm: The StratX analysis uses a validated algorithm to quantify fissure completeness, a predictor for volume reduction from EBV therapy.
Procedure:
  1. CT Scan Capture: Obtain a high-resolution chest CT scan according to StratX parameters.
  2. Data Upload: Upload the CT scan to the secure, cloud-based StratX platform, ensuring data is anonymized and encrypted.
  3. Data Analysis: The data is analyzed by validated algorithms, and a report is generated within 2-3 working days.
  4. Report Review: Access the report in PDF or HTML format from any clinical setting.
  5. Treatment Determination: Use the StratX information and clinical judgment to determine the most suitable treatment option.
Clinical Workflow: The StratX analysis, combined with the Chartis system, enhances accuracy. Patients with complete fissures or identified as CV- by Chartis can receive EBV therapy, while those with incomplete fissures should not be treated with EBV therapy.
Benefits:
  • Potentially offer EBV therapy to more patients.
  • Non-invasively screen treatment candidates.
  • Compare quantitative analyses across patients.
  • Educate referrers and patients about EBV therapy.
  • Enhance case planning and optimize procedure time.
  • Support compliance and good documentation practices.
Contact Information: For more information, contact Pulmonx International Sàrl at [email protected] or visit www.pulmonx.com.
See more

Catalog excerpts

StratX™ Lung Analysis Platform-1

Lung Analysis Platform Treat with Confidence

 Open the catalog to page 1
StratX™ Lung Analysis Platform-2

StratX™ Lung Analysis Platform A cloud-based quantitative CT analysis service that supports endobronchial valve (EBV) patient selection and treatment targeting by providing clinically-validated information on emphysema destruction, fissure completeness and lobar volumes ^ Pulmonx EBV therapy is the most rigorously studied minimally-invasive treatment for severe emphysema and is proven to improve patients’ breathing function, exercise capacity and quality of life.1 90% Accuracy in identifying EBV responders and non-responders when combined with selective use of the Chartis Pulmonary Assessment...

 Open the catalog to page 2
StratX™ Lung Analysis Platform-3

% Fissure Completeness Fissure Completeness Clinically-validated algorithm SIDE RIGHT LUNG The StratX analysis quantifies the completeness of each fissure using an Upload Date 27 July 2016 algorithm that has been validatedDate 27 July 2016 study of over 200 EBV in a retrospective Report Scan ID 0026671 2 16 February largest such analysis performed to date. Fissure completeness Scan Comments CT Scan Date patients, the2011 is a proven predictor for volume reduction resulting from EBV therapy.3 Patient ID 35-127-AJJ RIGHT LUNG for fissure completeness BACK % Fissure Completeness SIDE RIGHT LUNG...

 Open the catalog to page 3
StratX™ Lung Analysis Platform-4

Capture a high resolution chest CT scan according to the StratX CT parameters. Use web browser to upload CT scan to the secure, cloud-based StratX platform. • Automatically anonymized data with no patient health information transfer • Secure 256 bit SSL socket level encryption Workflow with rapid turnaround time Analyze Data + Generate Report StratX Lung Report TM Upload Date 27 July 2016 Report Date 27 July 2016 Scan ID 0026671 CT Scan Date 16 February 2011 Scan Comments SUMMARY KE Y ≥70% Voxel Density Less Than -910 HU 60-70% Voxel Density Less Than -910 HU 50-60% Voxel Density Less Than -910...

 Open the catalog to page 4
StratX™ Lung Analysis Platform-5

Lung Analysis Platform enables you to: 1 Potentially offer EBV therapy to more patients Non-invasively screen treatment candidates Chose between multiple potential treatment targets if applicable Enhance case planning and optimize procedure time Compare quantitative analyses across patients Educate referrers about the optimal candidate for EBV therapy Educate patients using user-friendly reports Support compliance and good documentation practices Contact us for more information: [email protected] Pulmonx International Sàrl Rue de la Treille 4 2000 Neuchâtel, Switzerland Tel: +41 32 475 20...

 Open the catalog to page 5

All PulmonX catalogs and technical brochures

*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.